Louisiana Wholesale Drug Co., Inc., et al. v. GlaxoSmithKline LLC, et al.

CourtDistrict Court, D. New Jersey
DecidedMarch 31, 2026
Docket2:12-cv-00995
StatusUnknown

This text of Louisiana Wholesale Drug Co., Inc., et al. v. GlaxoSmithKline LLC, et al. (Louisiana Wholesale Drug Co., Inc., et al. v. GlaxoSmithKline LLC, et al.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Louisiana Wholesale Drug Co., Inc., et al. v. GlaxoSmithKline LLC, et al., (D.N.J. 2026).

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

LOUISIANA WHOLESALE DRUG CO., INC., et al., Civil Action No. 12-00995

Plaintiffs/Appellants, OPINION AND ORDER v.

March 31, 2026 GLAXOSMITHKLINE LLC, et al.,

Defendants/Appellees.

SEMPER, District Judge. The current matter comes before the Court on Plaintiffs-Appellants’ appeal of the Honorable Cathy L. Waldor, U.S.M.J.’s (“Magistrate Judge Waldor”) July 30, 2025 decision that five new expert reports Defendants submitted were permissible in accordance with the operative scheduling order (ECF 668, “July 30 Order”). (ECF 669.) Defendants opposed the appeal. (ECF 676.) Plaintiffs filed a reply. (ECF 677.) The Court has decided the appeal pursuant to Federal Rule of Civil Procedure 72(a) and Local Civil Rule 72.1(c), and upon the submissions of the parties, without oral argument, pursuant to Federal Rule of Civil Procedure 78. For the reasons stated below, the appeal is GRANTED. The July 30 Order is VACATED. I. FACTUAL BACKGROUND AND PROCEDURAL HISTORY This fourteen-year-old dispute arises out of allegations that Defendants GlaxoSmithKline (“GSK”) and Teva Pharmaceuticals (“Teva”) entered into an illegal reverse-payment agreement to settle patent litigation so that GSK could maintain monopoly-level prices on its brand lamotrigine tablets known as Lamictal. (See generally, ECF 1.) The case was initially filed as a putative class action. (See id.) The parties engaged in, and completed, fact and expert discovery over the course of several years. (ECF 670-1, Declaration of Samuel E. Bonderoff (“Bonderoff Decl.”) Ex. 3 at 4.) Plaintiffs

moved for certification of their class in June 2018. (ECF 371.) Class certification was ultimately denied in 2023. (ECF 553; ECF 554.) Subsequently, several absent members of the putative class filed new complaints against Defendants in the District Court for the Eastern District of Pennsylvania. See e.g., MLI RX LLC v. GlaxoSmithKline LLC (“MLI”), No. 2:23-cv-2960 (D.N.J.). Defendants moved to transfer the new cases to this District under the first-filed rule and 28 U.S.C. § 1404(a). See id. at ECF 28. That motion was granted.1 See MLI, No. 2:23-cv-2960, ECF 59; see also Morris & Dickson, No. 2:23-cv-00480 (E.D. Pa.), ECF 41. Following transfer, on October 24, 2023, the parties submitted competing case-schedule and discovery proposals for the four direct purchaser Lamictal actions. See MLI, No. 2:23-cv-2960, ECF 85-1. Plaintiffs maintained that no additional fact discovery was necessary. (Id. at 3-6.)

Plaintiffs also proposed that the only issue on which additional expert reports should be issued was individual damages issues, since the other already-completed expert reports addressed issues common to all plaintiffs. (Id. at 6.) Defendants argued that new discovery of the newly added Plaintiffs was necessary. (Id. at 7-15.) Defendants proposed a schedule that “[left] appropriate time” for discovery, including “the preparation of any supplemental expert reports[.]” (Id. at 14.) As to experts, Defendants further stated, With respect to expert discovery, Plaintiffs of course are free to amend or supplement as few expert reports as they wish. Defendants, however, submit that supplementation of certain expert reports on issues other than damages may well be appropriate following

1 The new cases were formally consolidated with the existing case on November 2, 2023. (ECF 577.) discovery of the Newly Added Plaintiffs. For example, discovery of the Newly Added Plaintiffs will shed light on the nature of competition in the actual and but-for worlds, which in turn may impact the experts’ assumptions and conclusions about the relevant market, market power and competition in them.

(Id. at 14 n.21.) On July 31, 2023, Magistrate Judge Waldor held an initial pretrial conference and heard argument from the parties’ counsel regarding their competing case schedule and discovery proposals.2 (See Bonderoff Decl. Ex. 5.) After hearing arguments, Magistrate Judge Waldor found that consolidation3 called for discovery “with respect to the newly named plaintiffs.” (Id. at 15:7- 10.) Plaintiffs expressed concern with the scope of expert discovery in Defendants’ proposal, characterizing it as “unlimited.” (Id. at 16:13-17:5.) In response, Defense counsel argued: As to expert discovery, I think it’s clear that there are other areas where new discovery could impact what goes into our expert reports, like market definition. Now, I don’t think that we are requesting the right just to put in new reports on every single topic. What we’re saying is if there’s new evidence that we get through this process that impacts things we have previously done, we want to supplement those reports. I mean, that, by definition, is not overbroad. We’re just taking what we get in the new discovery -- in the fact discovery and applying it to the new expert discovery.

(Id. 19:6-16.) Magistrate Judge Waldor adopted Defendants’ proposed schedule, and directed the parties to “proceed with discovery, and I will deal with each problem as it comes – or each objection as it comes – or each deficiency as it comes. But let’s see what happens and not make any rules that may be limiting in the future.” (Id. at 20:23-21:5.)

2 Plaintiffs argued that no additional discovery was necessary following consolidation, and Defendants disagreed, arguing that class certification was denied on the basis of predominance and so there remained individual issues related to whether and what price each purchaser would have gotten from Teva. (See Bonderoff Ex. 5 at 10:20-12:9.) Defendants also argued that discovery from the new plaintiffs related to the “nature of competition in this market” was relevant. (Id. at 13:3-13.) 3 The cases were consolidated by an order dated November 2, 2023. (ECF 577.) On November 2, 2023, the Honorable Brian R. Martinotti, to whom this case was then assigned, held a status conference and directed the parties to submit a new order to Magistrate Judge Waldor “following the spirit of the Judge’s order [on July 31, 2023].” (ECF 581 at 4:4-8.) On November 8, 2023, the parties jointly submitted a proposed scheduling order.4 (ECF 578.) On

November 9, 2023, Magistrate Judge Waldor so-ordered the proposed scheduling order. (ECF 580 (the “New Scheduling Order”).) On May 30, 2025, after the conclusion of fact discovery of the newly joined Plaintiffs, Defendants served five new or amended expert reports (the “New Expert Reports”). (Br. at 9-15.) Plaintiffs take issue with these reports.5 On June 2, 2025, Plaintiffs submitted a letter to the Court expressing their concerns and opposition to the New Expert Reports. (ECF 645.) On June 4, 2025, Defendants filed a letter in response, arguing that the 2023 joinder complaints had changed their case. (ECF 647.) After further correspondence and meet-and-confer attempts (see Bonderoff Decl. Exs. 7-8), the Court held a hearing on June 5, 2025 regarding the parties’ disagreements (the “June 5 Hearing”). (Id. Ex. 9.) At the June 5 Hearing, Plaintiffs argued that Defendants were required to

move for leave under Rule 16(b) before serving the expert reports because the new reports relied on old, not new, discovery, and because Defendants replaced experts without explanation. (Id. at 11:12-15:10, 20:15-21, 21:9-12.) Defendants argued that Rule 16(b) was inapplicable since the new reports were within the bounds of the November 9, 2023 scheduling order. (Id. 22:1-26:15.) Magistrate Judge Waldor directed the parties to meet and confer again and “hone in on” the section

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. United States Gypsum Co.
333 U.S. 364 (Supreme Court, 1948)
Anderson v. City of Bessemer City
470 U.S. 564 (Supreme Court, 1985)
Gunter v. Ridgewood Energy Corp.
32 F. Supp. 2d 162 (D. New Jersey, 1998)
Kounelis v. Sherrer
529 F. Supp. 2d 503 (D. New Jersey, 2008)
Marks v. Struble
347 F. Supp. 2d 136 (D. New Jersey, 2004)
United States v. Robert Waterman
755 F.3d 171 (Third Circuit, 2014)
Cooper Hospital/University Medical Center v. Sullivan
183 F.R.D. 119 (D. New Jersey, 1998)

Cite This Page — Counsel Stack

Bluebook (online)
Louisiana Wholesale Drug Co., Inc., et al. v. GlaxoSmithKline LLC, et al., Counsel Stack Legal Research, https://law.counselstack.com/opinion/louisiana-wholesale-drug-co-inc-et-al-v-glaxosmithkline-llc-et-al-njd-2026.